| [1] |
Fassnacht M, Dekkers OM, Else T, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors[J]. Eur J Endocrinol, 2018, 179: G1-G46.
|
| [2] |
Xing Y, Lerario AM, Rainey W, et al. Development of adrenal cortex zonation[J]. Endocrinol Metab Clin North Am, 2015, 44: 243-274.
|
| [3] |
Ruggiero C, Doghman-Bouguerra M, Sbiera S, et al. VAV2 Dosage-dependent regulation of expression by steroidogenic factor-1 drives adrenocortical carcinoma cell invasion[J]. Sci Signal, 2017, 10: eaal2464. doi: 10.1126/scisignal.aal2464
|
| [4] |
Zheng S, Cherniack AD, Dewal N, et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma[J]. Cancer Cell, 2016, 29: 723-736.
|
| [5] |
Ghosh C, Hu J, Kebebew E. Advances in translational research of the rare cancer type adrenocortical carcinoma[J]. Nat Rev Cancer, 2023, 23: 805-824.
|
| [6] |
de Reyniès A, Assié G, Rickman DS, et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival[J]. J Clin Oncol, 2009, 27: 1108-1115.
|
| [7] |
Liu J, Kahri A, Heikkilá P, et al. Ribonucleic acid expression of the clustered imprinted genes, p57KIP2, insulin-like growth factor Ⅱ, and H19, in adrenal tumors and cultured adrenal cells[J]. J Clin Endocrinol Metab, 1997, 82: 1766-1771.
|
| [8] |
Jouinot A, Assié G, Libe R, et al. DNA methylation is an independent prognostic marker of survival in adreno-cortical cancer[J]. J Clin Endocrinol Metab, 2017, 102:923-932.
|
| [9] |
Drelon C, Berthon A, Mathieu M, et al. EZH2 is overexpressed in adrenocortical carcinoma and is associated with disease progression[J]. Hum Mol Genet, 2016, 25:2789-2800.
|
| [10] |
Patel D, Boufraqech M, Jain M, et al. miR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors[J]. Surgery, 2013, 154: 1224-1228.
|
| [11] |
Kwok GTY, Zhao JT, Glover AR, et al. MicroRNA-431 as a chemosensitizer and potentiator of drug activity in adrenocortical carcinoma[J]. Oncologist, 2019, 24: e241-e250.
|
| [12] |
Koperski Ŀ, Kotlarek M, Świerniak M, et al. Next-generation sequencing reveals microRNA markers of adrenocortical tumors malignancy[J]. Oncotarget, 2017, 8: 49191-49200.
|
| [13] |
Gara SK, Wang Y, Patel D, et al. Integrated genome-wide analysis of genomic changes and gene regulation in human adrenocortical tissue samples [J]. Nucleic Acids Res, 2015, 43: 9327-9339.
|
| [14] |
Patel D, Thompson MD, Manna SK, et al. Unique and novel urinary metabolomic features in malignant versus benign adrenal neoplasms[J]. Clin Cancer Res, 2017, 23: 5302-5310.
|
| [15] |
Smith DC, Kroiss M, Kebebew E, et al. A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma[J]. Invest New Drugs, 2020, 38: 1421-1429.
|
| [16] |
Heaton JH, Wood MA, Kim AC, et al. Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin[J]. Am J Pathol, 2012, 181: 1017-1033.
|
| [17] |
Boumahdi S, de Sauvage FJ. The great escape: tumour cell plasticity in resistance to targeted therapy[J]. Nat Rev Drug Discov, 2020, 19: 39-56.
|
| [18] |
Armignacco R, Cantini G, Poli G, et al. The adipose stem cell as a novel metabolic actor in adrenocortical carcinoma progression: evidence from an in vitro tumor microenvironment crosstalk model[J]. Cancers, 2019, 11: 1931. DOI: 10.3390/cancers11121931.
|
